This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Locally Advanced Rectal Cancer
and you are
between 18 and 99
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

An open-label, Phase 1b, dose escalation study evaluating the safety and tolerability of the PARP inhibitor Veliparib in combination with capecitabine and radiation in subjects with locally advanced rectal cancer (LARC).

Provided treatments

  • Drug: veliparib
  • Drug: capecitabine
  • Radiation: radiation

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01589419. The sponsor of the trial is AbbVie (prior sponsor, Abbott) and it is looking for 32 volunteers for the current phase.
Official trial title:
An Open-Label Phase 1b Study of the Safety and Tolerability of Veliparib in Combination With Capecitabine and Radiation in Subjects With Locally Advanced Rectal Cancer (LARC)